Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Neuridan is a medical food developed by NeuroEnergy Ventures for the dietary management of mild cognitive impairment (MCI) and mild-to-moderate Alzheimer's Disease. The product's active ingredient is a ketone ester, specifically glyceryl 3-hydroxybutyrate ester (also known as ketogenic glyceryl 3-hydroxybutyrate ester). Neuridan is designed to address the 'brain energy gap'—a condition in neurodegenerative diseases where the brain's ability to metabolize glucose is impaired. By providing ketone bodies as an alternative energy substrate, Neuridan supports brain nutrition and enables patients to maintain physiological hyperketonemia without the gastrointestinal side effects often associated with medium-chain triglycerides (MCTs) or ketone salts. It is administered orally under medical supervision as part of a comprehensive disease management plan.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Neuridan.